LogicBio Therapeutics

General Information


We are a genome editing company focused on developing medicines to durably treat rare diseases in patients with significant unmet medical need using GeneRide, our proprietary technology platform. Our GeneRide technology is designed to precisely integrate corrective genes into a patient’s genome to provide a stable therapeutic effect. Because GeneRide is designed to have this durable therapeutic effect, we are initially targeting rare liver disorders in pediatric patients where it is critical to provide treatment early in a patient’s life before irreversible disease pathology can occur.

Employees: 20
Founded: 2014
Contact Information
Address 610 Main Street, 3rd Floor, Cambridge, MA 02139, US
Phone Number (617) 245-0399.
Web Address http://www.logicbio.com
View Prospectus: LogicBio Therapeutics
Financial Information
Market Cap $219.38mil
Revenues $0 mil (last 12 months)
Net Income $-15.8 mil (last 12 months)
IPO Profile
Symbol LOGC
Exchange NASDAQ
Shares (millions): 7.0
Price range $10.00 - $10.00
Est. $ Volume $70.0 mil
Manager / Joint Managers Jefferies/ Barclays/ William Blair
CO-Managers Chardan
Expected To Trade: 10/19/2018
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change